Hims & Hers Health Faces FTC Allegations Amid Slowing Growth
Hims & Hers Health (NYSE: HIMS) has faced recent challenges, including a drop in stock price from its highs and allegations by the Federal Trade Commission (FTC). The agency claims that the telehealth company shared customer health data without consent. In response, Hims & Hers dismissed these accusations as 'baseless,' citing their privacy policy. Beyond regulatory concerns, broader issues with slowing growth have been affecting the stock for some time. Recent quarterly revenue growth has dropped to just 4%, and the company reported a $31 million operating loss over the past year. Despite its aggressive expansion strategy, Hims & Hers remains unprofitable and highly volatile as an investment. The stock currently trades at around 60 times estimated future earnings based on analyst expectations, suggesting it may still be overvalued despite recent declines.
Tickers: $HIMS
Topics: data privacy healthcare telemedicine